Kelvin Medical (KVMD) 10-Q 15 May 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2018	May 15, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Kelvin Medical, Inc.
Entity Central Index Key	1,679,836
Trading Symbol	KVMD
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		67,297,500

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Current assets
Cash and cash equivalents	$ 36,549	$ 17,280
Other receivable		3,000
Total current assets	36,549	20,280
TOTAL ASSETS	36,549	20,280
Current liabilities
Accounts payable	4,790	4,500
Accounts payable, related parties	33,318	19,039
Advances, related parties	4,614	5,309
Customer deposit	120	120
Total current liabilities	42,842	28,968
Total liabilities	42,842	28,968
Commitments and Contingencies
Stockholders' equity (deficit)
Common stock, $0.001 par value: shares authorized 100,000,000; 67,097,500 and 64,097,500 shares issued and outstanding as December 31, 2017 and June 30, 2017	67,298	64,098
Additional paid in capital	169,652	77,852
Retained deficit	(243,243)	(150,638)
Total stockholders' equity (deficit)	(6,293)	(8,688)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 36,549	$ 20,280

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Jun. 30, 2017
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	100,000,000	100,000,000
Common stock, shares issued	67,297,500	64,097,500
Common stock, shares, outstanding	67,297,500	64,097,500

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Net sales
Cost of goods sold
Gross profit
Operating expenses:
Management fees	8,000	3,000	14,000	9,000
Patent license fees	1,750	1,750	5,250	5,250
Professional fees	14,175	2,093	38,675	2,093
Research and development expenses	17,068		17,068
General and administrative expenses	14,472	1,286	17,612	1,316
Total operating expenses	55,465	8,129	92,605	17,659
Loss from operations	(55,465)	(8,129)	(92,605)	(17,659)
Income (loss) before taxes	(55,465)	(8,129)	(92,605)	(17,659)
Provision for income tax expense
Net (loss)	$ (55,465)	$ (8,129)	$ (92,605)	$ (17,659)
Net (loss) per common shares (basic and diluted)	$ 0	$ 0	$ 0	$ 0
Weighted average shares outstanding - Basic and diluted	67,197,500	63,049,611	65,498,960	63,016,296

Statement of Cash Flows

Statement of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash Flows from Operating Activities
Net loss	$ (92,605)	$ (17,659)
Adjustments to reconcile net loss to net cash used in operating activities:
Shares issued for services provided	3,000
Changes in operating assets and liabilities:
Other receivable	3,000	(3,000)
Accounts payable	2,290	3,379
Accounts payable, related parties	14,279	14,250
Subscriptions received		(7,400)
Liability for unissued shares		7,400
Net cash used in operating activities	(70,036)	(3,030)
Cash Flows from Investing Activities
Net cash provided from (used by) investing activities
Cash Flows from Financing Activities
Proceeds from private placement	90,000
Advances,related parties	10,483	3,060
Repayments, related parties	(11,178)
Net cash provided from (used by) financing activities	89,305	3,060
Increase (decrease) in cash and cash equivalents	19,269	30
Cash and cash equivalents at beginning of period	17,280	1,076
Cash and cash equivalents at end of period	36,549	1,106
Cash paid (received) during year for:
Interest
Income taxes
Non-Cash Investing and Financing Activities:
Shares issued to settle accounts payable	$ 2,000

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Activity: To date, our activities have been limited to formation, the development of a business plan and initial operations in order to commercialize our Therm-N-Ice product, along with research and development of plans to develop additional medical device and telehealth wearables. During the year ended June 30, 2017 we successfully obtained a listing on the OTC Pink Markets under the symbol "KVMD", and became DTC eligible. We commenced trading on Nov 28, 2017. We closed our initial public offering in fiscal 2017, and we are now exploring other sources of capital to fund our operations so that we can fully implement our business plan. In the current emerging growth phase, we anticipate we will continue to incur operating losses. On March 20, 2018, the SEC imposed a temporary halt on the trading of KVMD; the halt was terminated at 11:59 pm EDT on April 3, 2018. In order for the Company's stock to be trading again, the Company must have a Broker/Dealer file a Form 15c2-11 for the Company. Financial Statement Presentation: Fiscal year end: Use of Estimates: Cash Equivalents: Revenue recognition and related allowances: Accounts Receivable and Allowance for Doubtful Accounts: Inventories: Warranty: Advertising and Marketing Costs: Research and Development Costs: Income taxes: Basic and Diluted Loss Per Share New Accounting Pronouncements: In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities The Company has reviewed all other recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.

Going Concern

Going Concern	9 Months Ended
	Mar. 31, 2018
Going Concern [Abstract]
GOING CONCERN	2. GOING CONCERN The Company has experienced net losses to date, and it has not generated revenue from operations. The Company will need additional working capital to service debt and for ongoing operations, which raises substantial doubt about its ability to continue as a going concern. Management of the Company has developed a strategy to meet operational shortfalls which may include equity funding, short-term or long-term financing or debt financing, to enable the Company to reach profitable operations. If the Company fails to generate positive cash flow or obtain additional financing, when required, it may have to modify, delay, or abandon some or all of its business and expansion plans. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty.

Patent License Agreement

Patent License Agreement	9 Months Ended
	Mar. 31, 2018
Patent License Agreement [Abstract]
PATENT LICENSE AGREEMENT	3. PATENT LICENSE AGREEMENT On May 10, 2016, the Company entered into a patent license agreement with Oasis Medical Solutions, a sole proprietorship controlled by our board of directors and organized in the State of California ("Licensor") under which the Licensor desires to grant and the Company desires to accept an exclusive license of the Patent for the building of, and use of, machines incorporating the Patent's technology under certain terms and conditions. Both of the parties agree that the ownership of the Patent and the goodwill relating thereto, and any associated improvements, whether developed by the Company, or both parties jointly, shall remain vested in Licensor both during the term of the agreement and thereafter, and the Company further agrees never to challenge, contest or question the validity of the Licensor's ownership of the Patent or any associated registrations therewith. As consideration for the exclusive license granted, the Company shall pay to Licensor the following fees: (a) An ongoing maintenance fee of $500 per month plus an additional annual fee of $1,000; (b) Royalty fees of 6% per machine sold or leased under this license, payable within thirty (30) days of agreement reached with the customer/lessee. Payments can be grouped on a monthly occurring basis; (c) This license shall be considered null and void if production is not obtained within a 5-year period of the date stated above and the license, and all rights thereunder, will return to the Licensor. The term of the license agreement shall be for 15 years but will not extend beyond the full term of the patent. The patent will expire on June 19, 2034. Within a year from the end of the patent term, parties may negotiate an ongoing arrangement. During the three and nine months ended March 31, 2018, the Company incurred $1,750 and $5,250, respectively, in license fees (March 31, 2017 - $1,750 and $5,250).

Consulting Agreement

Consulting Agreement	9 Months Ended
	Mar. 31, 2018
Consulting Agreement [Abstract]
CONSULTING AGREEMENT	4. CONSULTING AGREEMENT (a) On June 1, 2016, the Company entered into a consulting agreement with a consultant who is in the business of assisting private companies in the process of going public and getting listed on the OTC Pink through the Form S-1 Registration. Under the terms of the consulting agreement, the Consultant shall provide certain services with respect to the Form S-1 Registration Statement, from commencement and preparation of the Form S-1 to receipt of Notice of Effectiveness, retention and payment of the required legal and accounting professionals, and thereafter to work with a market maker to provide a completed and accepted Form 15c2-11 with FINRA, a trading symbol and listing on OTC Pink. As compensation under the consulting agreement S-1 Services LLC, the consultant, received 3,000,000 shares of the Company's common stock at $0.02 per share for a value of $60,000. The $60,000 in costs relating to such Registration Statement was expensed during the fiscal year ended June 30, 2017 as the offering was not deemed successful. Further, a balance of $3,000 as of June 30, 2017 is included on the balance sheet as "Other receivable", in respect to amounts advanced to service providers by the Company which are required to be reimbursed by the Consultant under this agreement. As of March 31, 2018, the balance of other receivable is $nil as the receivable had been collected. (b) On October 23, 2017, the Company entered into a one-year agreement with a consultant for advice regarding certain legal, corporate and business operations, and more specifically with regard to public filings and compliance with regard to the Company. The consultant is to be compensated in the amount of Two Thousand Dollars ($2,000) per month, commencing November 1, 2017, including review of Form 10-K Annual Reports, Form 10-Q Quarterly Reports, Preparation of Form 8-K's, preparation of Board Resolutions and review of contractual agreements. During the nine months ended March 31, 2018, the Company paid $8,000 in cash and $2,000 was settled by the issuance of 100,000 shares as agreed in November 2017. The issued shares were valued at $0.02 per share, the value of the most recent transaction whereby the Company sold common shares. (c) On January 1, 2018, the Company entered into a one-year agreement with a consultant for advice regarding certain investor relations services. The Consultant is to be compensated in the amount of One Thousand Dollars ($1,000) per month, commencing January 1, 2018, along with the issuance of 100,000 shares of the Company's Common Stock. During the nine months ended March 31, 2018, the Company paid $2,000 in cash, leaving $1,000 in accounts payable. 100,000 shares were issued as per the terms of the agreement at a price of $0.03 per share, which share value represents the most recent transaction whereby the Company sold common shares. The $3,000 was recorded as professional fees.

Customer Deposits

Customer Deposits	9 Months Ended
	Mar. 31, 2018
Deferred Revenue Disclosure [Abstract]
CUSTOMER DEPOSITS	5. CUSTOMER DEPOSITS As at March 31, 2018 and June 30, 2017 the Company has received a customer deposit of $120 in respect to the sale of three units of the Therm-N-Ice arm band. The deposit represents a one-third deposit for each of the three units ordered.

Common Stock

Common Stock	9 Months Ended
	Mar. 31, 2018
Equity [Abstract]
COMMON STOCK	6. COMMON STOCK During the nine months ended March 31, 2018, the Company issued 100,000 shares at $0.02 per share to settle professional fees. (ref Note 4 – (b)) During the nine months ended March 31, 2018, the Company received proceeds totaling $90,000 in respect to a subscription for 3,000,000 restricted common shares at $0.03 per share. During the nine months ended March 31, 2018, the Company issued 100,000 shares at $0.03 per share in respect to a consulting agreement. (ref Note 4 – (c)) During the fiscal year ended June 30, 2017, the Company received proceeds of $21,950 from various parties subscribing for a total of 1,097,500 shares at $0.02 per share under our Form S-1 registration statement. As at March 31, 2018 and June 30, 2017 there were a total of 67,297,500 and 64,097,500 shares issued and outstanding respectively.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
RELATED PARTY	7. RELATED PARTY TRANSACTIONS a. Management and other services: Mr. William Mandel On May 15, 2016, the Company entered into a twelve-month agreement for management services with Mr. William Mandel, our President, Secretary, Treasurer and member of the Board of Directors. Under the terms of the agreement the Company issued 30,000,000 shares as a bonus to Mr. William Mandel valued at $30,000 or par value and shall pay $1,000 monthly in cash consideration. On November 15, 2017 the Company and Mr. Mandel entered into a new 12-month consulting agreement. Under the terms of the agreement Mr. Mandel shall receive $1,000 monthly as consideration until January 1, 2018, at which point in time the monthly consideration shall be increased to $2,000 monthly. The contract was extended for a further six-month term on expiry. There has been $11,000 (March 31, 2017- $9,000) accrued in relation to services rendered for the nine months ended March 31, 2018 by Mr. Mandel. The Company paid a total of $10,000 to reduce the outstanding account. Dr. Margaret Austin On November 15, 2017 the Company and Dr. Margaret Austin entered into a twelve-month agreement for services in which Dr. Austin will continue to serve as the Company's Chairman of the Board. Commencing January 1, 2018, Dr. Austin shall receive monthly consideration of $1,000 for her services. There has been $3,000 (March 31, 2017- $nil) accrued in relation to services rendered for the nine months ended March 31, 2018 by Dr. Austin. A total of $3,000 (as of June 30, 2017 - $nil) remains payable at March 31, 2018. b. Advances During the nine months ended March 31, 2018 Oasis Medical Solutions, a sole proprietorship controlled by our board of directors, advanced a total of $10,483 (2017 - $3,060). During the nine months ended March 31, 2018, the Company paid $11,178 to reduce the advances payable. As at March 31, 2018 a total of $4,614 remained due and payable (June 30, 2017 - $5,309) to this related entity. During fiscal 2017 an amount advanced in the prior fiscal year totaling $456 by Kelvin Medical LLC, a company controlled by our board of directors, was assigned to Mr. William Mandel directly for repayment when Kelvin Medical LLC was dissolved. This amount is included in Accounts payable – related party on our balance sheets. Advances received were used to provide working capital as required by the Company for ongoing operations. c. License fees The Company accrues patent license fees in respect to a patent license agreement with Oasis Medical Solutions (ref: Note 3 above). As at March 31, 2018 and June 30, 2017 a total $1,750 and $4,583 remained payable under the terms of this agreement, respectively. A total of $5,250 was incurred as new charges in the period ended March 31, 2018 (March 31, 2017 - $5,250) and the Company paid a total of $8,083 to reduce the outstanding account. d. Research and Development expenses During the nine months ended March 31, 2018 Oasis Medical Solutions invoiced the Company $17,068 in research and development services related to the task of solid works modeling and hardware development. The Company paid $3,956. As at March 31, 2018 $13,112

Other Events

Other Events	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
OTHER EVENTS	8. OTHER EVENTS On January 22, 2018, the Company entered into an Equity Purchase Agreement ("EPA"), and Registrations Rights Agreement with a Third Party, Phenix Ventures, LLC, wherein, Phenix Ventures has committed to purchasing 10,000,000 shares of the Company's Common Stock. Phenix will not hold any more than 9.99% of the issued and outstanding shares at any one time and funding will come by way of Put Notices as outlined in the EPA. The Company filed a Form S-1 Registration Statement on February 9, 2018 in order to register the 10,000,000 shares that Phenix will purchase under the EPA. The S-1 was withdrawn on March 15, 2018. The Company will not pursue the EPA at this time.

Income Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	9. INCOME TAXES Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company's assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company's tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. Operating loss carry-forwards generated during the period from May 5, 2016 (date of inception) through March 31, 2018 of approximately $243,200, will begin to expire in 2036. On December 22, 2017, the 2017 Tax Cuts and Jobs Act (the Tax Act) was enacted into law including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. The Company does not have any foreign earnings and therefore, we do not anticipate the impact of a transition tax. We have remeasured our U.S. deferred tax assets at a statutory income tax rate of 21%. Since the Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12 months, we consider the accounting of any transition tax, deferred tax re-measurements, and other items to be incomplete due to the forthcoming guidance and our ongoing analysis of final year-end data and tax positions. We expect to complete our analysis within the measurement period in accordance with SAB 118, and no later than fiscal year end June 30, 2018. The Company had deferred income tax assets as of March 31, 2018 and June 30, 2017 as follows: March 31, 2018 June 30, 2017 Loss carry forwards $ 51,100 $ 31,600 Less – accrued management fees (3,780 ) (2,940 ) Less - valuation allowance (47,320 ) (28,660 ) Total net deferred tax assets $ - $ - Tax years from inception to fiscal year ended June 30, 2017 are filed and remain open for examination by the taxation authorities. The Company has no tax positions at June 30, 2017 and 2016 for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company has no accruals for interest and penalties since inception.

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	10. SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there are no additional subsequent events to disclose.

Basis of Presentation and Sum16

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Financial Statement Presentation	Financial Statement Presentation:
Fiscal Year End	Fiscal year end:
Use of Estimates	Use of Estimates:
Cash Equivalents	Cash Equivalents:
Revenue recognition and related allowances	Revenue recognition and related allowances:
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts:
Inventories	Inventories:
Warranty	Warranty:
Advertising and Marketing Costs	Advertising and Marketing Costs:
Research and Development Costs	Research and Development Costs:
Income taxes	Income taxes:
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share
New Accounting Pronouncements	New Accounting Pronouncements: In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities The Company has reviewed all other recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of deferred income tax assets	March 31, 2018 June 30, 2017 Loss carry forwards $ 51,100 $ 31,600 Less – accrued management fees (3,780 ) (2,940 ) Less - valuation allowance (47,320 ) (28,660 ) Total net deferred tax assets $ - $ -

Basis of Presentation and Sum18

Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017
Basis of Presentation and Summary of Significant Accounting Policies (Textual)
Offering price	$ 0.02		$ 0.02
Shares being offered			30,000,000
Advertising and marketing costs
Allowance for doubtful accounts
Cash equivalent term features			90 days or less from the date of purchase
Potentially dilutive shares
Research and development expenses	$ 17,068		$ 17,068

Patent License Agreement (Detai

Patent License Agreement (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Patent License Agreement (Textual)
License fees		$ 1,750	$ 1,750	$ 5,250	$ 5,250
Patent expiry date				Jun. 19, 2034
License Agreement Terms [Member]
Patent License Agreement (Textual)
Monthly maintenance fee	$ 500
Annual license fee	$ 1,000
License agreement contingency, terms	This license shall be considered null and void if production is not obtained within a 5-year period of the date stated above and the license, and all rights thereunder, will return to the Licensor.
Payment terms, royalty fee	Royalty fees of 6% per machine sold or leased under this license, payable within thirty (30) days of agreement reached with the customer/lessee.
Term of license in years	15 years

Consulting Agreement (Details)

Consulting Agreement (Details) - USD ($)	Jun. 01, 2016	Mar. 31, 2018	Jun. 30, 2017	Jan. 02, 2018	Oct. 23, 2017
Consulting Agreement - Registration Statement
Shares issued to consultant for services received	3,000,000
Value of shares issued to consultant for services received	$ 60,000
Offering costs, expensed			$ 6,000,000
Other receivable			$ 300,000
Consultilng Agreement - Legal
Monthly fees starting November 1, 2017					$ 200,000
Cash payments in period		800,000
Legal fees settled in shares		$ 200,000
Shares issued for legal fees		100,000
Price per share, shares issued for legal fees		$ 0.02
Consultling Agreement - Investor Relations
Monthly Fee starting January 1, 2018				$ 100,000
Shares issued for IR fees				100,000
Value, issued shares				$ 300,000
Price per share, shares issued for IR fees				$ 0.03
Cash payments in period		$ 200,000
Amount payable for IR Fees		$ 100,000

Customer Deposits (Details)

Customer Deposits (Details) - USD ($)	9 Months Ended
	Mar. 31, 2018	Jun. 30, 2017
Customer Deposits (Textual)
Customer deposit	$ 120	$ 120
Deposits description	The deposit represents a one-third deposit for each of the three units ordered.

Common Stock (Details)

Common Stock (Details) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2018	Jun. 30, 2017
Shares Issued for Cash Proceeds
Per Share value, shares issued 2017	$ 0.03	$ 0.02
Shares issued	3,000,000	1,097,500
Proceeds, value	$ 90,000	$ 21,950
Shares issued, Professional fees	100,000
Price per share, shares issued for Professional fees	$ 0.02
Shares issued, Consulting Fees	100,000
Price per share, shares issued for Consulting fees	$ 0.03
Common stock, shares issued	67,297,500	64,097,500

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Nov. 15, 2017	Jun. 30, 2017	May 15, 2016
Related Party Transactions [Abstract]
Shares issued as bonus					30,000,000
Value, shares issued as bonus					$ 30,000
Monthly consulting fee					$ 1,000
Monthly fee January 1, 2018 forward			$ 2,000
Consulting fees incurred in period	$ 11,000	$ 9,000
Payments to reduce accounts payable in period	10,000
Accounts payable balance	15,000			$ 14,000
Advances payable				456
Monthly consulting fee, starting January 1, 2018			$ 1,000
Consulting fees incurred in period	3,000
Payments to reduce accounts payable in period
Accounts payable balance	3,000
Advances
Advances in period	10,483	3,060
Payments to reduce amounts owing in period	11,178
Balance payable	4,614			5,309
License fees
Patent license fees payable	1,750			$ 4,583
License fees incurred in period	5,250	$ 5,250
Payments to reduce balance outstanding in period	8,083
Research and Development Fees
Fees invoiced in period	17,068
Payments in period	3,956
Balance outstanding	$ 13,112

Other Events (Details Narrative

Other Events (Details Narrative)	Jan. 22, 2018shares
Equity Purchase Agreement, Phenix
Shares to be registered	10,000,000
Shares held resstricted to percent ownership	999.00%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Loss carryforwards	$ 51,100	$ 31,634
Less - accrued management fees	(3,780)	(2,940)
Less - valuation allowance	(47,320)	(28,694)
Total net deferred tax assets

Income Taxes (Details Textual)

Income Taxes (Details Textual)	9 Months Ended
	Mar. 31, 2018USD ($)
Income Taxes (Textual)
Operating loss carry-forwards	$ 243,200
Operating loss carry forwards, expiration date	Jun. 30, 2036
Statutory income tax rate	21.00%